Royalty Pharma (FRA:RPD) Notes Receivable: €0 Mil (As of Mar. 2026)


FRA:RPD Royalty Pharma PLC FRA:RPD
70 GF Score
Price €47.47
GF Value €31.66
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Notes Receivable?

Royalty Pharma FRA:RPD +0.35% 70 Notes Receivable is €0 Mil as of Mar. 2026. GuruFocus rates FRA:RPD with a GF Score™ of 70/100 and a GF Value™ of €31.66 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Royalty Pharma's Notes Receivable for the quarter that ended in Mar. 2026 was €0 Mil.

Royalty Pharma Notes Receivable Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Notes Receivable Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Royalty Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:RPD
70GF Score
Royalty Pharma PLC FRA:RPD
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0 Mil mean?
Royalty Pharma (FRA:RPD) has a Notes Receivable of €0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Notes Receivable too high?
Royalty Pharma's current Notes Receivable is €0 Mil. Overall, Royalty Pharma has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Notes Receivable compare to ROIV and MRNA?
Royalty Pharma's Notes Receivable of €0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Notes Receivable is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (FRA:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €31.66, compared to a current price of €47.47 — trading 49.9% above its estimated fair value. The current Notes Receivable is €0 Mil. Royalty Pharma's overall GF Score™ is 70/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Royalty Pharma (FRA:RPD), the current Notes Receivable is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (FRA:RPD) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of €47.47 is trading 49.9% above its estimated GF Value™ of €31.66. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for FRA:RPD:

  • Notes Receivable: €0 Mil
  • GF Value™: €31.66 vs. price of €47.47 (49.9% above fair value)
  • GF Score™: 70/100 with 10 warning signs

No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USA
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
70GF Score

Get the complete analysis for FRA:RPD

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€47.47
Price
€31.66
GF Value